Recursos de NCI

NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - October 2001 Clonal heterogeneity of p53 mutations in ovarian cancer. The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer....
NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - September 2001 Table of Contents[Sonographic characterization, Doppler ultrasonography and tumor markers in the diagnosis of malignancy of ovarian masses]Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - October 2001 Clonal heterogeneity of p53 mutations in ovarian cancer. Is it good clinical judgment or selection bias? Molecular pathways involved in response to ionizing radiation of ID-8 mouse ovarian cancer cells expressing exogenous full-length Brca1 or...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - September 2001 Table of ContentsCase-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism.Epidemiology of ovarian cancer: a summary review.Ovarian carcinoma recurring as carcinosarcoma.Use of fertility...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - October 2001 Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side Germ cell tumors of the ovary: is there a role for aggressive cytoreductive surgery for...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - September 2001 Table of ContentsLysophosphatidic acid and ovarian cancer: a paradigm for tumorogenesis and patient management.Factors determining the actual received dose intensity in a program of multicyclic dose-intensive alternating chemotherapy with...
NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - April 2002 [Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma] Clinical management of women with genomic BRCA1 and BRCA2 mutations. Ovarian teratomas with florid benign vascular proliferation: a distinctive finding associated with the...
NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - August 2002 BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Predicting response of ovarian cancer to paclitaxel treatment based on trend analysis of serum...
NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - February 2002 Allelic imbalance is not restricted to numerically abnormal chromosomes in epithelial ovarian tumours. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. UV-induced DNA...
NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - January 2002 A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels...
NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - July 2002 Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian Expression of prostaglandin D synthase in ovarian cancer. Mutation screening analysis of the retinoblastoma...
NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - June 2002 Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. [CA-125 antigen] Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology...
NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - March 2002 [Chlamydiaceae and cancer] Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. Epithelial ovarian carcinoma and fertility of parents. Association of parity and ovarian cancer...
NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - May 2002 Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, Intakes of selected nutrients and food groups and risk of ovarian cancer. Coffee and alcohol intake and...
NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - October 2002 Oral contraceptives and epithelial ovarian cancer. Does dose matter? Dietary antioxidants, supplements, and risk of epithelial ovarian cancer. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol)...
NCI CANCERLIT^® Search: Diagnosis-Histopathology-Pathogenesis of Ovarian Cancer - September 2002 Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. ...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - April 2002 [Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma] Clinical management of women with genomic BRCA1 and BRCA2 mutations. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - August 2002 Genes and generalists: why we need professionals with added competencies. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Expression of MUC1...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - February 2002 Allelic imbalance is not restricted to numerically abnormal chromosomes in epithelial ovarian tumours. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. UV-induced DNA...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - January 2002 A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Conditions for single-strand conformation polymorphism (SSCP) analysis of BRCA1 gene using an automated electrophoresis unit. The...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - July 2002 Expression of prostaglandin D synthase in ovarian cancer. Mutation screening analysis of the retinoblastoma related gene RB2/p130 in sporadic ovarian cancer and head and neck squamous cell cancer. BRCA1 transcriptionally regulates genes...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - June 2002 Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. Adenovirus gene therapy for ovarian cancer. In vivo molecular chemotherapy and noninvasive imaging with...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - March 2002 Association of parity and ovarian cancer risk by family history of breast or ovarian cancer in a population-based study of postmenopausal BRCA1 and BRCA2 mutations in Russian familial breast cancer. Novel germline BRCA1 and BRCA2 mutations in...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - May 2002 Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin-sensitive and -resistant adenocarcinoma cells. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - October 2002 Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. A girl with bilateral ovarian tumours: Frasier syndrome. Evidence of a role for the INK4 family of...
NCI CANCERLIT^® Search: Hereditary Ovarian Cancer - September 2002 Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer. The...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - April 2002 A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer. Evaluation of therapy response in...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - August 2002 Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells. Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - February 2002 [Ifosfamide combination chemotherapy for advanced gynecologic malignancies] Paclitaxel plus organoplatins: still the gold standard in advanced ovarian cancer? Management of familial breast and ovarian cancer cases. [Relationship between...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - January 2002 Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - July 2002 Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - June 2002 [Surgical treatment of ovarian cancer should be centralized] Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. Macrophage colony-stimulating factor prevents febrile neutropenia induced by chemotherapy. Phase...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - March 2002 Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - May 2002 Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin-sensitive and -resistant adenocarcinoma cells. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - October 2002 Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients...
NCI CANCERLIT^® Search: Therapy of Ovarian Cancer - September 2002 IDM 1. IDM-1, MAK/IDM-1. Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells. [Combined treatment and prognostic analysis of advanced epithelial ovarian carcinoma] [Clinical significance of secondary...
NCI/PDQ^® Health professionals: Ovarian Cancer Prevention (PDQ®) TABLE OF CONTENTS Summary of EvidenceOral Contraceptives: BenefitsOral Contraceptives: HarmsProphylactic Oophorectomy: BenefitsProphylactic Oophorectomy: HarmsSignificanceIncidence and MortalityEvidence of BenefitPathogenesisProtective FactorsOral...
NCI/PDQ^® Health professionals: Ovarian Cancer Screening (PDQ®) TABLE OF CONTENTS Summary of EvidenceCA 125 Levels, Transvaginal Ultrasound, and Pelvic Examinations Statement of benefitStatement of harmsSignificanceIncidence and MortalityFactors Associated With Ovarian CancerEvidence of BenefitUltrasonographyCA...
NCI/PDQ^® Health professionals: Ovarian Epithelial Cancer Treatment (PDQ®) TABLE OF CONTENTS General Information About Ovarian Epithelial Cancer Incidence and MortalityRelated SummariesCellular Classification of Ovarian Epithelial CancerStage Information for Ovarian Epithelial CancerDefinitions: FIGOStage I and Stage II...
NCI/PDQ^® Health professionals: Ovarian Germ Cell Tumors Treatment (PDQ®) TABLE OF CONTENTS General Information About Ovarian Germ Cell TumorsDysgerminomasOther Germ Cell TumorsCellular Classification of Ovarian Germ Cell TumorsStage Information for Ovarian Germ Cell TumorsDefinitions: FIGOTreatment Option OverviewStage I...
NCI/PDQ^® Health professionals: Ovarian Low Malignant Potential Tumors Treatment (PDQ®) TABLE OF CONTENTS General Information About Ovarian Low Malignant Potential TumorsStage Information for Ovarian Low Malignant Potential Tumors Definitions: FIGOEarly-Stage Ovarian Low Malignant Potential TumorsCurrent Clinical TrialsAdvanced-Stage...
NCI/PDQ^® Pacientes: Cáncer epitelial de los ovarios: Tratamiento (PDQ®) TABLE OF CONTENTS Información general sobre el cáncer epitelial de los ovariosEstadios del cáncer epitelial de ovariosCáncer epitelial de ovarios recidivante o persistente Aspectos generales de las opciones de tratamientoOpciones...
NCI/PDQ^® Pacientes: Tumores de células germinales del ovario: Tratamiento (PDQ®) TABLE OF CONTENTS Información general sobre los tumores de células germinales del ovario Estadios de los tumores de células germinales del ovarioTumores de células germinales de los ovarios recidivantesAspectos generales de las...
NCI/PDQ^® Pacientes: Tumores del ovario de bajo potencial maligno: Tratamiento (PDQ®) TABLE OF CONTENTS Información general sobre los tumores del ovario de bajo potencial malignoEstadios de los tumores del ovario de bajo potencial malignoTumores de ovario de bajo potencial maligno recidivantesAspectos generales de las opciones...
NCI/PDQ^® Patients: Ovarian Cancer Prevention (PDQ®) TABLE OF CONTENTS What is prevention?General Information About Ovarian CancerOvarian Cancer PreventionChanges to This Summary (01/04/2013)Questions or Comments About This SummaryGet More Information From NCIAbout PDQ® What is prevention? Back...
NCI/PDQ^® Patients: Ovarian Cancer Screening (PDQ®) TABLE OF CONTENTS What is screening?General Information About Ovarian CancerOvarian Cancer ScreeningRisks of Ovarian Cancer ScreeningChanges to This Summary (01/04/2013)Questions or Comments About This SummaryGet More Information From NCIAbout...
NCI/PDQ^® Patients: Ovarian Epithelial Cancer Treatment (PDQ®) TABLE OF CONTENTS General Information About Ovarian Epithelial Cancer Stages of Ovarian Epithelial CancerRecurrent or Persistent Ovarian Epithelial CancerTreatment Option OverviewTreatment Options by StageStage I and II Ovarian Epithelial...
NCI/PDQ^® Patients: Ovarian Germ Cell Tumors Treatment (PDQ®) TABLE OF CONTENTS General Information About Ovarian Germ Cell TumorsStages of Ovarian Germ Cell TumorsRecurrent Ovarian Germ Cell TumorsTreatment Option OverviewTreatment Options By StageStage I Ovarian Germ Cell TumorsStage II Ovarian Germ Cell...
NCI/PDQ^® Patients: Ovarian Low Malignant Potential Tumors Treatment (PDQ®) TABLE OF CONTENTS General Information About Ovarian Low Malignant Potential TumorsStages of Ovarian Low Malignant Potential TumorsRecurrent Ovarian Low Malignant Potential TumorsTreatment Option OverviewTreatment Options for Ovarian Low Malignant...
NCI/PDQ^® Profesionales De Salud: Cáncer epitelial de los ovarios: Tratamiento (PDQ®) TABLE OF CONTENTS Información general sobre el cáncer epitelial de los ovariosIncidencia y mortalidadSumarios relacionadosClasificación celular del cáncer epitelial de ovarioInformación sobre los estadios del cáncer...
NCI/PDQ^® Profesionales De Salud: Tumores de células germinales del ovario: Tratamiento (PDQ®) TABLE OF CONTENTS Información general sobre los tumores germinales del ovarioDisgerminomasOtros tumores de células germinalesClasificación celular de los tumores de células germinales del ovarioEnsayos clínicos en...
NCI/PDQ^® Profesionales De Salud: Tumores del ovario de bajo potencial maligno: Tratamiento (PDQ®) TABLE OF CONTENTS Información general sobre los tumores de ovario de bajo potencial malignoInformación sobre los estadios de los tumores de ovario de bajo potencial malignoDefiniciones: FIGOTumores del ovario de bajo potencial maligno en...